Navigation Links
New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results
Date:8/19/2007

Findings Represent Strongest Support for Coiling Since Groundbreaking 2002

Trial

DANA POINT, Calif., Aug. 1 /PRNewswire/ -- A new study reveals that coiling, a minimally invasive procedure to treat aneurysms in the brain, is successful in preventing recurrent or first-time bleeding years after initial treatment in those aneurysms considered "untouchable" by the traditional surgical option. One of the most significant findings since the 2002 release of the International Subarachnoid Aneurysm Trial or ISAT (the trial that established coiling as a safe and effective treatment), this new study's scientific value is reflected in its large patient population and length of post-procedural follow-up -- two factors that have not existed together in other post-ISAT studies to date. Results were unveiled yesterday at the fourth Annual Meeting of the American Society of Interventional & Therapeutic Neuroradiology (ASITN) in Dana Point, California.

"This study represents a unique contribution to the scientific evidence that proves coiling to be a viable treatment option," said study presenter Jo Peluso, a neurointerventional radiologist who collected and analyzed the data on behalf of colleagues W.J.J. van Rooij and M. Sluzewski, who have been performing neurointerventional procedures since the early 1990s at Saint Elisabeth Hospital in Tilburg, the Netherlands. "The clinical credibility of any procedure relies not only on the initial trials that may sanction its use on patients, but also - and perhaps equally as important - on those long-term follow-up studies that prove the procedure's success over time. This study achieves one such milestone."

A retrospective analysis, the study includes 154 consecutive patients who underwent coiling over an 11-year period (January 1995 - August 2006) on aneurysms on the tip of the basilar artery, located in front of the brain stem. Comprising approximately 8.4 percent of all brain aneurysms in the general population, basilar tip aneurysms pose particular difficulties as their position deep in the brain makes a traditional, open neurosurgical approach more dangerous for the patient. Coiling, achieved by placing a mesh of platinum wires in the aneurysm (described as a "bulge" in an artery wall), prevents the aneurysm from rupturing, a serious and often life-threatening condition.

Of the 154 patients undergoing the procedure, 114 (or 74 percent) of the aneurysms had ruptured and 40 (or 26 percent) had not. Following treatment, 144 surviving patients received clinical follow-up up to 144 months, adding up to a total of 637 patient years. Angiographic follow-up (actually viewing the site of the aneurysm using X-ray and MRI technology) conducted on 138 patients up to 122 months revealed that 27 aneurysms (17.5 percent) re-opened over time; these patients underwent additional coiling. Of this number, 11 aneurysms repeatedly re-opened and were coiled up to a total of six times. Re- bleeding occurred in only two patients, indicating an overall annual risk of 0.3 percent for re-bleeding after treatment. In all cases, aneurysm size greater than 10 mm was the only significant predictor for re-treatment at follow-up.

As these results underscore the effectiveness of coiling as a treatment option that ensures success over time, Peluso says the study also shows that in some cases coiling can be considered a staged treatment. "Our strict clinical and angiographic follow-up strategy with additional treatment when necessary was effective in preventing recurrent hemorrhage in ruptured aneurysms, or primary hemorrhage in unruptured aneurysms."

Coiling is performed by physicians specially trained to treat conditions in the brain through endovascular (or "through the artery") and minimally invasive means. Coiling and other treatments are achieved by working through a catheter or narrow tube that is inserted into the groin and threaded up through the arteries directly to the problem site in the brain.

Approximately 2 million people in the United States have an unruptured aneurysm. It is estimated that approximately 30,000 Americans suffer from subarachnoid hemorrhage each year.

ASITN members specialize in minimally invasive and endovascular procedures to treat stroke, aneurysms, carotid stenosis and spine fractures. Our physicians have made numerous contributions to the neurosciences including: advancing stroke treatment through catheter based therapy; innovating endovascular coiling for aneurysms; pioneering interventional procedures to treat fractures in the spine; and initiating the first-ever stroke registry to track procedural success in the treatment of acute stroke. More information on ASITN and our members' treatment specialties may be found at http://www.asitn.org.


'/>"/>
SOURCE American Society of Interventional & Therapeutic
Neuroradiology

Copyright©2007 PR Newswire.

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , the ... chains, has published the first annual edition of its Global CSR Risk ... 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly ... ... Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... services for healthcare compliance program management, will showcase a range of technology and ... for Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 ...
(Date:10/12/2017)... ... October 12, 2017 , ... The American College of Medical Informatics ... PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s ... of Morris F. Collen, a pioneer in the field of medical informatics, this prestigious ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):